Akeso, Inc. (AKESF)
OTCMKTS
· Delayed Price · Currency is USD
7.80
0.00 (0.00%)
Dec 26, 2024, 4:00 PM EST
Akeso Revenue
Akeso had revenue of 1.02B CNY in the half year ending June 30, 2024, with 528.16% growth. This brings the company's revenue in the last twelve months to 1.87B, down -56.93% year-over-year. In the year 2023, Akeso had annual revenue of 4.53B with 440.35% growth.
Revenue (ttm)
1.87B CNY
Revenue Growth
-56.93%
P/S Ratio
n/a
Revenue / Employee
674.64K CNY
Employees
2,778
Market Cap
6.87B USD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAkeso News
- 24 days ago - Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer - PRNewsWire
- 4 weeks ago - Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference - PRNewsWire
- 4 weeks ago - Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab - PRNewsWire
- 5 weeks ago - Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA - PRNewsWire
- 5 weeks ago - Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit - PRNewsWire
- 7 weeks ago - Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting - PRNewsWire
- 2 months ago - Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab - PRNewsWire
- 2 months ago - Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab - PRNewsWire